EU court prepares to tackle legal wrangles over SPCs
This article was originally published in SRA
Europe's supplementary protection certificates have proved a useful way of extending effective patent life for pharmaceutical products, but as with many other forms of intellectual property protection, uncertainties in the legislation have given rise to many legal disputes. Unfortunately progress in clarifying the situation has been slow, and several cases are still pending before the national and European courts.
You may also be interested in...
Hungary is going its own way when it comes to coronavirus vaccines, but its decision to allow the emergency use of the Oxford University/AstraZeneca vaccine may be only a symbolic expression of the government’s growing impatience with the EU.
Valneva is scaling up manufacture of its coronavirus vaccine alongside the clinical development program, with a view to meeting its commitment to provide millions of doses for use in the UK and the EU.
The UK government says it will begin a consultation on a future falsified medicines scheme for Great Britain within a year after the passage of new legislation on medicines and medical devices. Moves are also under way to ensure the smooth supply of medicines from GB to Cyprus, Ireland, Malta and Northern Ireland.